A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.

OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver metabolic disease affecting millions globally. This study aimed to assess the safety and efficacy of a high oral loading dose of cholecalciferol supplement on NAFLD patients and to investigate its potential role on serum inflammatory biomarkers. PATIENTS AND METHODS: One hundred patients with NAFLD and type 2 diabetes mellitus were involved in the study. Eligible patients were randomized among two equal groups. Group 1 received the standard conventional therapy in addition to a placebo. Group 2 received the conventional therapy plus cholecalciferol for 4 months. The improvement in the patients' glycaemic control parameters, liver function tests, lipid profile, and serum 25-hydroxy vitamin D at the end of the study was set as a primary outcome. The secondary outcome was the decrease in steatosis grade in the ultrasound and high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), signal transducer and activator of factor-3 (STAT-3), nitric oxide (NO), malondialdehyde (MDA), and hepassocin serum levels at the end of the study. RESULTS: Group 2 revealed a significant reduction in the serum levels of lipid profile measures, hs-CRP, alanine aminotransferase (ALT), STAT-3, NO, hepassocin, and MDA compared to the baseline and group 1 results. Whereas group 1 did not show these significant changes. Both groups observed no significant changes in glycemic index, TNF-α, aspartate aminotransferase (AST), and albumin levels. CONCLUSIONS: Cholecalciferol is recommended as additional therapy to modulate lipid peroxidation and systemic inflammation alongside other NAFLD therapies.

Unravelling the antibacterial potential of biosynthesized selenium nanoparticles against Salmonella Typhimurium food pathogen: in vitro and in vivo investigation.

OBJECTIVE: It is highly required to find novel alternatives to the antibiotics currently used due to the increasing dissemination of antibiotic resistance among bacteria, especially enteric bacteria. The current study aimed to produce selenium nanoparticles (SeNPs) by Euphorbia milii Des Moul leaves extract (EME). MATERIALS AND METHODS: The produced SeNPs were characterized using different techniques. After that, in vitro and in vivo antibacterial activity against Salmonella typhimurium was elucidated. Moreover, phytochemical identification and quantification of the chemical compositions of EME were performed using HPLC. The broth microdilution method determined the minimum inhibitory concentrations (MICs). RESULTS: The MIC values of SeNPs ranged from 128 to 512 µg/mL. Additionally, the impact of SeNPs on membrane integrity and permeability was investigated. A marked decline in the membrane integrity and inner and outer membrane permeability was noticed in 50%, 46.15%, and 50% of the tested bacteria, respectively. Subsequently, a gastrointestinal tract infection model was used to study the in vivo antibacterial potential of SeNPs. Remarkably, treatment with SeNPs resulted in average-sized intestinal villi and colonic mucosa in the small intestine and caecum, respectively. In addition, it was revealed there was no inflammation or dysplasia in the studied tissues. SeNPs also enhanced the survival rate and significantly decreased the number of colony-forming units per gram tissues in the small intestine and caecum. Concerning the inflammatory markers, SeNPs significantly (p < 0.05) decreased interleukins (6 and 1ß). CONCLUSIONS: The biosynthesized SeNPs revealed antibacterial potential in vivo and in vitro; however, this finding should be elucidated clinically in the future.